We conducted a cross-sectional study to prospectively determine the specific complement activating pathway, which includes different complement proteins (C1q, C3, C3b, C4, FH), in the pathology of T2DM only, cognitive impairment only, and T2DM combined with cognitive impairment. This evidence concerns the gene VTN and type 2 diabetes mellitus.